Conquering hepatitis C, step by step

New England Journal of Medicine

Volumn 343, Issue 23, 2000, Pages 1723-1724

  Schafer, D F ^a   Sorrell, M F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

BLOOD TOXICITY; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FATIGUE; HEADACHE; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; MYALGIA; PRIORITY JOURNAL; TREATMENT INDICATION;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS;

EID: 0034620057     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200012073432309     Document Type: Editorial

References (11)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial
3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
4. Peginterferon alfa-2a in patients with chronic hepatitis C
5. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
6. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
7. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
8. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C
9. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C
10. Hepatitis C in African Americans: Summary of a workshop
11. Hepatitis C virus and eliminating post-transfusion hepatitis